
Publications
Trodusquemine enhances Aβ42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes
– Nat Commun
(2019)
10,
225
(doi: 10.1038/s41467-018-07699-5)
Small molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer’s disease
(2019)
729392
(doi: 10.1101/729392)
Massively parallel C elegans tracking provides multi-dimensional fingerprints for phenotypic discovery
– Journal of neuroscience methods
(2018)
306,
57
O2‐02‐02: TARGETING AMYLOID FORMATION USING RATIONALLY DESIGNED ANTIBODIES
– Alzheimer's & Dementia
(2018)
14,
p611
(doi: 10.1016/j.jalz.2018.06.2646)
Multistep Inhibition of α-Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine
– ACS Chemical Biology
(2018)
13,
2308
(doi: 10.1021/acschembio.8b00466)
Regional differences in dopamine release in the R6/2 mouse caudate putamen.
– Electroanalysis
(2018)
30,
1066
(doi: 10.1002/elan.201700827)
Modulating Amyloid-Beta Aggregation to Reduce the Toxicity of its Oligomeric Aggregates
– Biophysical Journal
(2018)
114,
430a
(doi: 10.1016/j.bpj.2017.11.2382)
Systematic Development of Small Molecules to Inhibit Specific Microscopic Steps of Amyloid-Beta42 Aggregation in Alzheimer's Disease
– Biophysical Journal
(2018)
114,
225A
(doi: 10.1016/j.bpj.2017.11.1253)
A natural product inhibits the initiation of α-synuclein aggregation & suppresses its toxicity
– Proceedings of the National Academy of Sciences of the United States of America
(2017)
114,
e1009
(doi: 10.1073/pnas.1610586114)
Attenuating the Toxicity of Amyloid-Beta Aggregation with Specific Species
– Biophysical Journal
(2017)
112,
494a
(doi: 10.1016/j.bpj.2016.11.2673)
- 1 of 2